WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ABUS

Based on 3 analysts offering 12 month price targets for Arbutus Biopharma Corp.
Min Forecast
$6.00+212.5%
Avg Forecast
$6.00+212.5%
Max Forecast
$6.00+212.5%

Should I buy or sell ABUS stock?

Based on 3 analysts offering ratings for Arbutus Biopharma Corp.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ABUS stock forecasts and price targets.

ABUS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 2%
2
BuyReiterates$6.00+212.50%2023-09-12
Chardan Capital
Top 3%
98
Strong BuyReiterates$6.00+212.50%2023-08-04
JMP Securities
Bottom 3%
3
BuyReiterates$6.00+212.50%2023-07-06

1 of 1

Forecast return on equity

Is ABUS forecast to generate an efficient return?
Company
N/A
Industry
0.66%
Market
28.71%

Forecast return on assets

Is ABUS forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.05%

ABUS revenue growth forecast

How is ABUS forecast to perform vs Biotechnology companies and vs the US market?
Company
-14.6%
Industry
34.31%
Market
8.24%
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABUS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABUS$1.92$6.00+212.50%Strong Buy
APLM$3.60$21.50+497.22%Strong Buy
ORIC$5.89$15.50+163.16%Strong Buy
NBTX$9.19N/AN/A
VYGR$7.24$16.00+120.99%Strong Buy
View Top Biotech Stocks

Arbutus Biopharma Stock Forecast FAQ

Is Arbutus Biopharma Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ABUS) stock is to Strong Buy ABUS stock.

Out of 3 analysts, 1 (33.33%) are recommending ABUS as a Strong Buy, 2 (66.67%) are recommending ABUS as a Buy, 0 (0%) are recommending ABUS as a Hold, 0 (0%) are recommending ABUS as a Sell, and 0 (0%) are recommending ABUS as a Strong Sell.

If you're new to stock investing, here's how to buy Arbutus Biopharma stock.

What is ABUS's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ABUS) forecast ROE is N/A, which is considered weak.

What is ABUS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ABUS price target, the average ABUS price target is $6.00, with the highest ABUS stock price forecast at $6.00 and the lowest ABUS stock price forecast at $6.00.

On average, Wall Street analysts predict that Arbutus Biopharma's share price could reach $6.00 by Sep 12, 2024. The average Arbutus Biopharma stock price prediction forecasts a potential upside of 212.5% from the current ABUS share price of $1.92.

What is ABUS's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ABUS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.05%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.